Bernstein analyst Lee Hambright maintains Medtronic (NYSE:MDT) with a Outperform and lowers the price target from $100 to $99.
Bernstein analyst Lee Hambright maintains Medtronic (NYSE:MDT) with a Outperform and lowers the price target from $100 to $99.